

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 1c893f1b-bc87-4c67-bbd6-d93ad17e1bb8 -->
<!-- Creation date: 2013-11-07T01:01:33Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:mnov="http://www.medicinova.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mnov-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DeferredRevenue contextRef="eol_PE402953--1310-Q0010_STD_0_20111031_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_5AFED1D2-7B43-41EA-8618-BDED39FDCAF9_1001_400000">2500000</us-gaap:DeferredRevenue>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20111031_0_734171x796264" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_5001_6">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE402953--1310-Q0010_STD_0_20111031_0_734171x796264" unitRef="pure" decimals="2" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_5001_7">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE402953--1310-Q0010_STD_0_20111031_0_734171x796264" unitRef="shares" decimals="INF" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_5001_9">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20111031_0_734171x796264" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_5001_3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20120822_0" unitRef="shares" decimals="0" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1002_0">130000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20120822_0" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1002_1">1.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <mnov:ClassOfWarrantOrRightFairValue contextRef="eol_PE402953--1310-Q0010_STD_0_20120822_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1002_4">100000</mnov:ClassOfWarrantOrRightFairValue>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20130509_0_734171x772521" unitRef="shares" decimals="0" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_3001_2">869047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20130509_0_734171x772521" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_3001_3">3.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0010_STD_0_20131106_0" unitRef="shares" decimals="INF" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_2_500005">22397943</dei:EntityCommonStockSharesOutstanding>
  <mnov:ConsistsOfEachFirmCommitmentUnderwrittenPublicOfferingUnit contextRef="eol_PE402953--1310-Q0010_STD_0_20110323_0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_1_2">Each unit consisting of one share of common stock and a  warrant to purchase one share of common stock</mnov:ConsistsOfEachFirmCommitmentUnderwrittenPublicOfferingUnit>
  <mnov:NumberOfUnitsInFirmCommitmentUnderwrittenPublicOffering contextRef="eol_PE402953--1310-Q0010_STD_0_20110323_0" unitRef="shares" decimals="0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_1_0">2750000</mnov:NumberOfUnitsInFirmCommitmentUnderwrittenPublicOffering>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE402953--1310-Q0010_STD_0_20120331_0" unitRef="pure" decimals="2" id="id_3255982_C32F0946-24F0-49BA-9E9F-61EB676AB49C_1001_1">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE402953--1310-Q0010_STD_0_20130417_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="-6" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3001_0">6000000</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20130529_0_797208x760742" unitRef="shares" decimals="0" id="id_3255982_89A371CB-E775-46EE-96EF-17A5BF717506_3001_1">119047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0010_STD_0_20130529_0_797208x760742" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_3255982_89A371CB-E775-46EE-96EF-17A5BF717506_3001_3">3.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <mnov:OtherAssetAmortizationPeriod contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1001_5">P1Y</mnov:OtherAssetAmortizationPeriod>
  <mnov:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1001_3">P5Y</mnov:ClassOfWarrantOrRightExpirationPeriod>
  <mnov:StockPurchaseAgreementNumberOfSharesCanBePurchasedPerDay contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_711502x716112" unitRef="shares" decimals="INF" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_4001_5">50000</mnov:StockPurchaseAgreementNumberOfSharesCanBePurchasedPerDay>
  <mnov:StockPurchaseAgreementValueOfSharesCanBePurchasedPerDay contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_711502x716112" unitRef="iso4217_USD" decimals="INF" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_4001_6">500000</mnov:StockPurchaseAgreementValueOfSharesCanBePurchasedPerDay>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_711502x716112_734171x796264" unitRef="pure" decimals="2" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_5001_10">0.30</mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-6" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_6001_0">20000000</us-gaap:CommonStockSharesSubscriptions>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfNextBusinessDayNasdaqVolumeWeightedAveragePrice contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="2" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_6001_11">0.95</mnov:VolumeWeightedAveragePurchaseAsPercentageOfNextBusinessDayNasdaqVolumeWeightedAveragePrice>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay contextRef="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="2" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_6001_9">0.15</mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1002_37">5744523</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_29">22377943</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_25">220000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_1001_400006">2103865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_1001_5">5.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_1001_400005">2904137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_22">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_24">220000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_1001_6">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_28">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_34">0</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_23">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_30">22377943</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_18">1694163</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_16">1099404</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_32">-77838</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_14">440086</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_1_2">171031</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_31">326300292</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_12">186892</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_1_1">183198</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_36">21447053</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_35">-303675590</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_21">2200</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_13">472426</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_19">4749567</us-gaap:Liabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_26">22378</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_37">26196620</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_17">1956000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Goodwill contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_5">9600241</us-gaap:Goodwill>
  <us-gaap:TreasuryStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_33">1124389</us-gaap:TreasuryStockValue>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_7">676481</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_8">80801</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_9">26196620</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_2">10660849</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_3255982_57340C41-A1E5-4508-A613-E25F89CEA6CF_1_2">116000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_57340C41-A1E5-4508-A613-E25F89CEA6CF_1_0">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_4001_5">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:CashFDICInsuredAmount contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_1753C01D-2CFF-4BC4-81E8-78E140D521C6_1_0">250000</us-gaap:CashFDICInsuredAmount>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_3">378248</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_4">11039097</us-gaap:AssetsCurrent>
  <mnov:AccruedResearchAndDevelopmentExpenseCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_1_0">118197</mnov:AccruedResearchAndDevelopmentExpenseCurrent>
  <mnov:MaturityPeriodOfInvestmentInCashEquivalentsSecurities contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" id="id_3255982_3A779211-E907-42B8-9D7F-4A8F66925437_1_0">Three  months or less</mnov:MaturityPeriodOfInvestmentInCashEquivalentsSecurities>
  <mnov:InProcessResearchAndDevelopment contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_1_6">4800000</mnov:InProcessResearchAndDevelopment>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_3255982_2E67E21A-0084-4B66-9672-7ED3B0916945_2001_1">699000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3255982_2E67E21A-0084-4B66-9672-7ED3B0916945_2002_1">699000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE402953--1310-Q0010_STD_0_20131016_0_705999x732135_710720x714667_734171x806301" unitRef="iso4217_USD" decimals="-6" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_4001_0">10000000</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="eol_PE402953--1310-Q0010_STD_0_20071231_0" unitRef="pure" decimals="2" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_1001_0">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3001_36">15093124</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_29">17407311</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_25">220000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_2001_1">4.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_2001_400001">3328981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_22">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_24">220000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_28">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_34">4186</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_23">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_30">17403125</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_18">1694257</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_16">1037792</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_32">-67957</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_14">228124</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_2_2">94504</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_31">312293225</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_12">491853</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_2_1">68102</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_36">14879992</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_35">-296233797</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_15">3163</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_21">2200</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_13">314652</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_19">4688049</us-gaap:Liabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_26">17407</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_37">19568041</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_17">1956000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Goodwill contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_5">9600241</us-gaap:Goodwill>
  <us-gaap:TreasuryStockValue contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_33">1131086</us-gaap:TreasuryStockValue>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_7">667204</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_8">78474</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_9">19568041</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_2">4010530</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_3">411592</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_4">4422122</us-gaap:AssetsCurrent>
  <mnov:AccruedResearchAndDevelopmentExpenseCurrent contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7A01C885-1673-42B9-8856-7B94B2CFE2C7_2_0">152046</mnov:AccruedResearchAndDevelopmentExpenseCurrent>
  <mnov:InProcessResearchAndDevelopment contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_BCC43E63-633D-496A-B432-120C0CCED8BD_2_6">4800000</mnov:InProcessResearchAndDevelopment>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_3255982_2E67E21A-0084-4B66-9672-7ED3B0916945_1001_2">1720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3255982_2E67E21A-0084-4B66-9672-7ED3B0916945_1002_2">1720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x713713_717061x709629" unitRef="shares" decimals="0" id="id_3255982_87F981F5-9E7A-48A3-A82E-9940E45D48C7_1001_0">1158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x713713_734171x772521" unitRef="shares" decimals="0" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_1001_0">1158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x715581_717061x709629" unitRef="shares" decimals="INF" id="id_3255982_87F981F5-9E7A-48A3-A82E-9940E45D48C7_2001_1">869047</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_2001_1">3.15</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD" decimals="-5" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_2001_5">300000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE402953--1310-Q0010_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD" decimals="-5" id="id_3255982_26B0F650-4023-4561-AF8C-00343E8338FA_2001_4">3700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <dei:TradingSymbol contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_1_400000">MNOV</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_1_400001">MEDICINOVA INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_4BFFD67D-C474-4298-AB2E-40C0317936E5_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_1_400004">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_4BFFD67D-C474-4298-AB2E-40C0317936E5_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_4BFFD67D-C474-4298-AB2E-40C0317936E5_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_4BFFD67D-C474-4298-AB2E-40C0317936E5_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_1_400002">0001226616</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_3EBCB1C0-2716-45A7-8360-2D052808BB53_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_4BFFD67D-C474-4298-AB2E-40C0317936E5_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_ED92BAB2-41A3-4BF0-A502-0F10E215C57D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Potentially
 dilutive outstanding securities excluded from diluted net loss per
 common share because of their anti-dilutive effect consist of the
 following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Convertible preferred
 stock, as converted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,904,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,876,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,128,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,980,204&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,657,667&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_57340C41-A1E5-4508-A613-E25F89CEA6CF_2_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_79AFD518-E778-4B80-8B17-9D08FA599EEC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;A summary of
 the changes in stock options outstanding during the nine months
 ended September&amp;#xA0;30, 2013 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Stock&lt;br /&gt;
 Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 December&amp;#xA0;31, 2012&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.92&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;867,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;79,462&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.44&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,212,882&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.99&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 September&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,904,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.55&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercisable at
 September&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,103,865&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.22&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_3_3">30251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_5912BFED-BAA7-4B23-B569-44A8727DE0A7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3. Fair Value
 Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As defined in
 the authoritative guidance for fair value measurements and
 disclosures under ASC 820, fair value is based on the price that
 would be received to sell an asset or would be paid to transfer a
 liability in an orderly transaction between market participants at
 the measurement date. To increase the comparability and consistency
 of fair value measurements, ASC 820 prescribes a fair value
 hierarchy that prioritizes observable and unobservable inputs used
 to measure fair value into three broad levels which are described
 below:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="7%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1:&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are quoted prices (unadjusted) in active markets
 for identical assets or liabilities at the measurement
 date.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level&amp;#xA0;2:&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are quoted prices for similar items in active
 markets or inputs are quoted prices for identical or similar items
 in markets that are not active.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level&amp;#xA0;3:&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are unobservable due to little or no market data
 availability and inputs are usually developed by management or a
 third-party which reflect those inputs that a market participant
 would use. The fair value hierarchy gives the lowest priority to
 Level 3 inputs.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 table presents our financial instruments measured at fair value on
 a recurring basis classified by the fair value measurements and
 disclosures valuation hierarchy (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of December 31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At
 September&amp;#xA0;30, 2013, cash equivalents (instruments with
 maturities of three months or less at the date of purchase) were
 primarily invested in money market accounts, the fair value of
 which is based on Level 1 criteria in which their carrying amount
 is a reasonable estimate of their fair value based on daily quoted
 market prices. At September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 we did not hold financial instruments measured at fair value
 on a non-recurring basis.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_1_2">2.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_49B30E67-C341-445F-83CE-A86CB7A5943F_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;2. Joint
 Venture&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;We entered into
 an agreement to form a joint venture company with Zhejiang Medicine
 Co., Ltd. and Beijing Make-Friend Medicine Technology Co., Ltd.
 effective September&amp;#xA0;27, 2011. In accordance with the joint
 venture agreement, in March 2012 we paid $680,000 for a 30%
 interest in Zhejiang Sunmy. The other parties to the joint venture
 agreement provided funding for their combined 70% interest and are
 responsible for future funding of Zhejiang Sunmy&amp;#x2019;s
 activities. Zhejiang Sunmy is a variable interest entity for which
 we are not the primary beneficiary as we do not have a majority of
 the board seats and we will not have power to direct or
 significantly influence the actions of the entity. We therefore
 account for the activities of Zhejiang Sunmy under the equity
 method whereby we absorb any loss or income generated by Zhejiang
 Sunmy according to our percentage ownership. At September&amp;#xA0;30,
 2013 we reflect a long-term asset on our consolidated balance sheet
 which represents our investment in Zhejiang Sunmy, net of our
 portion of any generated loss or income.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_3_4">234327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:RevenueRecognitionDeferredRevenue contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_72CEB6C1-0FEC-44E4-85CF-156DB284FEB8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition
 and Deferred Revenue&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October
 2011, we entered into an agreement with Kissei Pharmaceutical Co.,
 Ltd., or Kissei, to perform research and development services
 relating to MN-221 in exchange for a non-refundable upfront payment
 of $2.5&amp;#xA0;million. We assessed the deliverables in accordance
 with the authoritative guidance and concluded the existence of one
 deliverable, which was research and development services. Under the
 terms of the agreement, we are responsible for all costs to be
 incurred in the performance of these services. Certain of these
 research and development services were completed in 2012 and the
 remaining services are expected to be completed after 2014. We are
 recognizing the $2.5 million payment as revenue as the research and
 development services are performed. The amount received from
 Kissei, net of the amount recorded as revenue to date, is included
 on the balance sheet as deferred revenue and will be recognized as
 revenue as we perform the remaining services. For the three months
 ended September&amp;#xA0;30, 2013 and 2012, revenue recorded was $0 and
 $0.1 million, respectively. For the nine months ended
 September&amp;#xA0;30, 2013 and 2012, revenue recorded was
 approximately $3 thousand and $0.8 million,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_056183DB-C85E-4A3A-8B1E-DB49F96CC877_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;5. Balance Sheet
 Details&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Accrued
 Expenses&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued
 expenses consist of the following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
 costs&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;118,197&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;152,046&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Professional services
 fees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;183,198&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,102&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;171,031&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;94,504&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;472,426&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;314,652&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_F70F8C75-4540-4A05-9207-92D6167A8C31_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 table provides the assumptions used in the Black-Scholes valuation
 model for the three and nine months ended September&amp;#xA0;30, 2013
 and 2012. The ESPP assumptions for the three months ended
 September&amp;#xA0;30, 2013 and 2012 are actual amounts, and for the
 nine months ended September&amp;#xA0;30, 2013 and 2012 are weighted
 average amounts.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="40%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Stock Options
 assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.70&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected&amp;#xA0;volatility&amp;#xA0;of&amp;#xA0;common&amp;#xA0;stock&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85.76&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;82.22&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;82.14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
 (in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.3&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.3&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;ESPP
 assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.15&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected&amp;#xA0;volatility&amp;#xA0;of&amp;#xA0;common&amp;#xA0;stock&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.60&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;74.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.55&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;75.52&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
 (in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_81DCB6F1-8C6F-4A5C-8C63-6748948C40EF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
 table presents our financial instruments measured at fair value on
 a recurring basis classified by the fair value measurements and
 disclosures valuation hierarchy (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;699&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of December 31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_797E2670-CB8D-474D-8CF3-DDDB73F10934_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
 consolidated financial statements include the accounts of
 MediciNova, Inc. and its wholly-owned subsidiaries. MediciNova,
 Inc. and its subsidiaries are collectively referred to herein as
 &amp;#x201C;we,&amp;#x201D; &amp;#x201C;our&amp;#x201D; or &amp;#x201C;us.&amp;#x201D;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 December&amp;#xA0;13, 2006, MediciNova (Europe) Limited, a wholly-owned
 subsidiary of MediciNova, Inc.,&amp;#xA0;was incorporated under the
 laws of England and Wales and established for the purpose of
 facilitating the clinical development of our product candidates for
 the European marketplace. MediciNova (Europe) Limited&amp;#x2019;s
 functional currency is the U.S. dollar, the reporting currency of
 its parent.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 January&amp;#xA0;4, 2007, MediciNova Japan, Inc., a wholly-owned
 subsidiary of MediciNova, Inc., was incorporated under the laws of
 Japan and established to strengthen business development and
 investor and public relations activities in Japan and other Asian
 countries. MediciNova Japan, Inc.&amp;#x2019;s functional currency is
 the Japanese yen.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On December 18,
 2009, Avigen, Inc. was acquired by and became a wholly-owned
 subsidiary of MediciNova, Inc. Avigen, Inc.&amp;#x2019;s functional
 currency is the U.S.&amp;#xA0;dollar.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All
 intercompany transactions and investments in our subsidiaries have
 been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_916FC42B-CDB3-4B6D-884B-08EEA8BD5DD0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1. Interim Financial
 Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;The
 Company&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We were
 incorporated in the state of Delaware in September 2000. We are a
 development stage biopharmaceutical company focused on acquiring
 and developing novel, small molecule therapeutics for the treatment
 of serious diseases with unmet medical needs with a specific focus
 on the U.S. market. We are currently focusing our development
 activities on MN-166, a drug candidate for the treatment of
 neurological disorders, and on MN-221, a drug candidate for the
 treatment of acute exacerbations of asthma and chronic obstructive
 pulmonary disease, or COPD.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
 Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
 prepared the accompanying unaudited consolidated financial
 statements in accordance with accounting principles generally
 accepted in the U.S. for interim financial information.
 Accordingly, they do not include all of the information and
 disclosures required by generally accepted accounting principles
 for complete financial statements. In the opinion of management,
 all adjustments of a normal recurring nature necessary for the fair
 presentation of our financial position, results of operations and
 cash flow for the interim periods presented have been included.
 Operating results for the three and nine months ended
 September&amp;#xA0;30, 2013 are not necessarily indicative of the
 results that may be expected for the year ending December&amp;#xA0;31,
 2013 or for any other period. For further information, see the
 financial statements and disclosures thereto for the year ended
 December&amp;#xA0;31, 2012 in our Annual Report on Form 10-K as filed
 with the Securities and Exchange Commission on March&amp;#xA0;28,
 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
 consolidated financial statements include the accounts of
 MediciNova, Inc. and its wholly-owned subsidiaries. MediciNova,
 Inc. and its subsidiaries are collectively referred to herein as
 &amp;#x201C;we,&amp;#x201D; &amp;#x201C;our&amp;#x201D; or &amp;#x201C;us.&amp;#x201D;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 December&amp;#xA0;13, 2006, MediciNova (Europe) Limited, a wholly-owned
 subsidiary of MediciNova, Inc.,&amp;#xA0;was incorporated under the
 laws of England and Wales and established for the purpose of
 facilitating the clinical development of our product candidates for
 the European marketplace. MediciNova (Europe) Limited&amp;#x2019;s
 functional currency is the U.S. dollar, the reporting currency of
 its parent.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 January&amp;#xA0;4, 2007, MediciNova Japan, Inc., a wholly-owned
 subsidiary of MediciNova, Inc., was incorporated under the laws of
 Japan and established to strengthen business development and
 investor and public relations activities in Japan and other Asian
 countries. MediciNova Japan, Inc.&amp;#x2019;s functional currency is
 the Japanese yen.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On December 18,
 2009, Avigen, Inc. was acquired by and became a wholly-owned
 subsidiary of MediciNova, Inc. Avigen, Inc.&amp;#x2019;s functional
 currency is the U.S.&amp;#xA0;dollar.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All
 intercompany transactions and investments in our subsidiaries have
 been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Use of
 Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Actual results may
 differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition
 and Deferred Revenue&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October
 2011, we entered into an agreement with Kissei Pharmaceutical Co.,
 Ltd., or Kissei, to perform research and development services
 relating to MN-221 in exchange for a non-refundable upfront payment
 of $2.5&amp;#xA0;million. We assessed the deliverables in accordance
 with the authoritative guidance and concluded the existence of one
 deliverable, which was research and development services. Under the
 terms of the agreement, we are responsible for all costs to be
 incurred in the performance of these services. Certain of these
 research and development services were completed in 2012 and the
 remaining services are expected to be completed after 2014. We are
 recognizing the $2.5 million payment as revenue as the research and
 development services are performed. The amount received from
 Kissei, net of the amount recorded as revenue to date, is included
 on the balance sheet as deferred revenue and will be recognized as
 revenue as we perform the remaining services. For the three months
 ended September&amp;#xA0;30, 2013 and 2012, revenue recorded was $0 and
 $0.1 million, respectively. For the nine months ended
 September&amp;#xA0;30, 2013 and 2012, revenue recorded was
 approximately $3 thousand and $0.8 million,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Concentrations and
 Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We maintain
 cash balances at various financial institutions and such balances
 commonly exceed the $250,000 insured amount by the Federal Deposit
 Insurance Corporation. We also maintain money market funds at
 various financial institutions which are not federally insured,
 although they are invested primarily in U.S.&amp;#xA0;government
 securities. We have not experienced any losses in such accounts and
 management believes that we do not have significant credit risk
 with respect to such cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_D5E4D3E0-564C-4641-89CD-9221C31FA3F3_1_0">&lt;div&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;Accrued expenses
 consist of the following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Research and development
 costs&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;118,197&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;152,046&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Professional services
 fees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;183,198&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;68,102&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;171,031&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;94,504&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;472,426&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;314,652&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_18">20114289</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_7F21BC83-C176-4C77-BB84-034ACD042DF1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;10. Stockholders&amp;#x2019;
 Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock
 Options&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have granted
 stock options to our employees, officers, directors and consultants
 under the MediciNova,&amp;#xA0;Inc. Amended and Restated 2004 Stock
 Incentive Plan, and future stock option grants will be made under
 the MediciNova, Inc. 2013 Equity Incentive Plan. A summary of the
 changes in stock options outstanding during the nine months ended
 September&amp;#xA0;30, 2013 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Stock&lt;br /&gt;
 Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 December&amp;#xA0;31, 2012&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.92&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;867,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;79,462&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.44&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,212,882&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.99&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
 September&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,904,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.55&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercisable at
 September&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,103,865&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.22&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The aggregate
 intrinsic values of stock options outstanding, options exercised
 and options exercisable at September&amp;#xA0;30, 2013 were
 approximately $132,000, $64,000 and $116,000, respectively. The
 weighted average contractual life of options outstanding at
 September&amp;#xA0;30, 2013 was 6.5 years and the weighted average
 contractual life of exercisable options at September&amp;#xA0;30, 2013
 was 5.5 years.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Kissei Stock
 Purchase&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In
 October&amp;#xA0;2011, pursuant to a stock purchase agreement by and
 between us and Kissei, Kissei purchased for $7.5 million
 (i)&amp;#xA0;an aggregate of 800,000 shares of our common stock, par
 value $0.001 per share, at a price of $2.50 per share, which
 approximated the fair value of our common stock at the time of the
 transaction, and (ii)&amp;#xA0;220,000 shares of our Series&amp;#xA0;B
 Convertible Preferred Stock, or Series B Preferred, par value $0.01
 per share, at a price of $25.00 per share, which approximated the
 fair value of our preferred stock on an as converted basis at the
 time of the transaction. The purchase agreement contains customary
 representations, warranties and covenants and a standstill
 agreement from Kissei that terminates if Kissei beneficially owns
 less than three percent of our outstanding voting stock. Each share
 of the Series B Preferred is convertible into 10&amp;#xA0;shares of
 common stock. The Series B Preferred ranks &lt;i&gt;pari passu&lt;/i&gt; (on an
 as-if-converted-to-common-stock basis) with the common stock in
 liquidation and dividend rights. The holders of the Series B
 Preferred do not have voting rights, however the consent of the
 holders of a majority of the outstanding Series B Preferred is
 required for certain actions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Common Stock Purchase
 Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 August&amp;#xA0;20, 2012, we entered into a common stock purchase
 agreement with Aspire Capital Fund LLC, or Aspire, pursuant to
 which we could sell our common stock to Aspire from time to time up
 to an aggregate of $20 million of our common stock over the
 two-year term of the agreement, including $1 million in common
 stock purchased by Aspire in connection with execution of the
 agreement. No more than 3,231,096 shares of our common stock could
 be issued under this agreement, including 363,636 shares initially
 issued to Aspire in consideration of entering into the agreement.
 We could on any business day over the term of the agreement direct
 Aspire to purchase up to 50,000 shares, to a maximum of $500,000
 per business day with a purchase price of the lower of the lowest
 sale price of our common stock on the date of the sale, or the
 average of the three lowest closing stock prices during the 12
 consecutive business days ending on the business day immediately
 preceding the purchase date. In addition, we could on any business
 day over the term of the Agreement direct Aspire to make a
 volume-weighted average purchase (&amp;#x201C;VWAP&amp;#x201D;) of stock not
 to exceed 15% (which limitation may be increased up to 30% by the
 mutual agreement of the parties) of the aggregate shares of our
 stock traded on the next business day, the purchase price of which
 would be the lower of the closing price on the date of the sale, or
 95% of the next business day&amp;#x2019;s NASDAQ volume weighted average
 price, subject to a minimum market price threshold established by
 us and certain other exceptions. In addition to the initial
 issuance of shares, as of September&amp;#xA0;30, 2013 we had completed
 sales to Aspire totaling 2,504,532 shares of common stock at prices
 ranging from $1.60 to $3.82 per share, generating gross proceeds of
 $5.4 million. See &amp;#x201C;Notes to Consolidated Financial Statements
 - Note 11. Subsequent Events&amp;#x201D; regarding termination of the
 common stock purchase agreement with Aspire subsequent to
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Issuance of
 Warrant&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 August&amp;#xA0;22, 2012, we issued a warrant in exchange for investor
 relations services to purchase up to 130,000 shares of our common
 stock at a price of $1.88 per share, the closing price of our
 common stock on that date. The warrant contains provisions whereby
 the warrant becomes exercisable for specified shares of our common
 stock as a result of our stock achieving certain share price
 targets within a 15 month period beginning on August&amp;#xA0;22, 2012.
 The warrant expires in five years. The warrant is valued at its
 fair value of approximately $0.1&amp;#xA0;million on August&amp;#xA0;22,
 2012, was classified as equity and as a prepaid expense and
 amortized over the one-year period beginning August&amp;#xA0;22,
 2012.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Exercise of
 Warrants&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the
 three months ended September&amp;#xA0;30, 2013, no warrants were
 exercised. During the nine months ended September&amp;#xA0;30, 2013,
 warrants to purchase 121,666 shares of common stock related to the
 March&amp;#xA0;23, 2011 public offering of 2,750,000 units, with each
 unit consisting of one share of common stock and a warrant to
 purchase one share of common stock, were exercised generating
 proceeds of $0.4 million. No warrants were exercised during the
 three and nine months ended September&amp;#xA0;30, 2012&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;At-The-Market Equity
 Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 April&amp;#xA0;17, 2013, we entered into an at-the-market equity
 distribution agreement with Macquarie Capital (USA) Inc., or MCUSA,
 pursuant to which we could sell our common stock through MCUSA from
 time to time up to an aggregate offering price of $6 million. Under
 the terms of the agreement, no daily sale of an amount of shares of
 our common stock was to exceed the lower of $50,000 or 10% of the
 lower of the 5-day or 3-month average daily traded value of our
 common stock as of the date of the applicable issuance notice. The
 price per share was not to be less than the greater of $1.19 or the
 last available closing price of a share of common stock on The
 NASDAQ Global Market (&amp;#x201C;NASDAQ&amp;#x201D;). MCUSA agreed to use
 its commercially reasonable efforts consistent with its customary
 trading and sales practices and applicable laws, rules and
 regulations to sell shares of our common stock and was to sell such
 shares by any method permitted by law deemed to be &amp;#x201C;at the
 market&amp;#x201D;. We agreed to pay MCUSA an aggregate commission rate
 of 8.0% of the gross proceeds of any common stock sold under the
 agreement. As of September&amp;#xA0;30, 2013, we had completed all
 available sales to MCUSA under this agreement generating gross and
 net proceeds of $6.0 million and $5.5 million, respectively, on
 sales of 1,936,237&amp;#xA0;shares of common stock at prices ranging
 from $2.44 to $4.10 per share.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See
 &amp;#x201C;Notes to Consolidated Financial Statements - Note 11.
 Subsequent Events&amp;#x201D; regarding a second at-the-market equity
 distribution agreement executed with MCUSA subsequent to
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Securities Purchase
 Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#xA0;9,
 2013, we entered into a securities purchase agreement with certain
 accredited investors (the&amp;#xA0;&amp;#x201C;Purchase Agreement&amp;#x201D;)
 pursuant to which we agreed to sell to the investors 1,158,730
 shares of our common stock at a price of $3.15 per share and
 warrants to purchase an aggregate of 869,047 shares of our common
 stock with an exercise price of $3.15 per share (the &amp;#x201C;Private
 Placement&amp;#x201D;). The Private Placement closed on May&amp;#xA0;14,
 2013. The warrants will expire on May&amp;#xA0;9, 2018 and may be
 exercised for cash or, if the current market price of our common
 stock is greater than the per share exercise price, by surrender of
 a portion of the warrant in a cashless exercise. The aggregate
 purchase price for the shares and the warrants sold in the Private
 Placement was $3.7 million and associated expenses incurred were
 $0.3 million. The Purchase Agreement includes representations,
 warranties, covenants and closing conditions customary for
 transactions of this type.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In connection
 with the purchase by an affiliated investor of 158,730 shares of
 our common stock and a warrant to purchase 119,047 shares of our
 common stock, on May&amp;#xA0;29, 2013 the investor provided $51,389
 additional consideration for the shares and the warrant, and we
 amended the warrant to reflect an exercise price of $3.38 per
 share.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We allocated
 the net proceeds for the shares and the warrants sold in the
 Private Placement of $3.4 million based on the relative fair value
 of each instrument. We determined the fair value of the shares
 based on the closing price of our common stock on May&amp;#xA0;9, 2013,
 and the fair value of the warrants based on a Black-Scholes
 valuation model.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_16">-6624818</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_06206CAC-803F-4803-80F8-F4853A6D75AE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;4. Net Loss Per
 Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 common share is presented as basic and diluted net loss per common
 share. Basic net loss per common share is calculated by dividing
 the net loss attributable to common stockholders by the weighted
 average number of common shares outstanding for the period, without
 consideration for common stock equivalents. Diluted net loss per
 common share is calculated by dividing the net loss attributable to
 common stockholders by the weighted average number of common shares
 outstanding for the period using the treasury-stock method. For
 purposes of this calculation, convertible preferred stock, stock
 options and warrants are considered to be common stock equivalents
 and are only included in the calculation of diluted net loss per
 common share when their effect is dilutive.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Potentially
 dilutive outstanding securities excluded from diluted net loss per
 common share because of their anti-dilutive effect consist of the
 following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Convertible preferred
 stock, as converted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,904,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,876,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,128,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,980,204&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,657,667&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_1_400003">79462</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_6EABBA3D-2875-478E-A79F-C65A338319BA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Concentrations and
 Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We maintain
 cash balances at various financial institutions and such balances
 commonly exceed the $250,000 insured amount by the Federal Deposit
 Insurance Corporation. We also maintain money market funds at
 various financial institutions which are not federally insured,
 although they are invested primarily in U.S.&amp;#xA0;government
 securities. We have not experienced any losses in such accounts and
 management believes that we do not have significant credit risk
 with respect to such cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_A3C2E4D0-EA85-4D09-AD5B-0D697208D8FF_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;8. Related Party
 Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;On May&amp;#xA0;9,
 2013, we entered into a securities purchase agreement with certain
 accredited investors pursuant to which we agreed to sell to the
 investors 1,158,730 shares of our common stock and warrants to
 purchase an aggregate of 869,047 shares of our common stock (the
 &amp;#x201C;Private Placement&amp;#x201D;). The Private Placement closed on
 May&amp;#xA0;14, 2013. The Private Placement included our issuance of
 shares of common stock and a warrant to purchase shares of common
 stock to Fountain Erika LLC (&amp;#x201C;Fountain Erika&amp;#x201D;), an
 entity of which Tatsuo Izumi, a member of our board of directors,
 is a principal. Fountain Erika&amp;#x2019;s acquisition of the shares of
 the our common stock and a warrant to purchase shares of our common
 stock was at an &amp;#x201C;at the market&amp;#x201D; price.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_1_4">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_1_3">8980204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:UseOfEstimates contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_16FBF6BD-4808-41CC-AD84-94D4B9E417DD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Use of
 Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
 of consolidated financial statements in conformity with U.S.
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Actual results may
 differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_17">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_D04BF326-12F1-490D-BB6A-51F1068045B8_1_3">2.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_1_400002">867500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_F8AA49F8-CCF3-442B-951A-A9E68D7206C9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;11. Subsequent
 Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;At-The-Market Equity
 Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
 October&amp;#xA0;16, 2013, we entered into a second at-the-market
 equity distribution agreement with MCUSA pursuant to which we may
 sell our common stock through MCUSA from time to time up to an
 aggregate offering price of $10 million. Under the terms of this
 agreement, unless otherwise mutually agreed, no daily sale of an
 amount of shares of our common stock is to exceed the lower of
 $50,000 or 10% of the lower of the 5-day or &lt;font style="WHITE-SPACE: nowrap"&gt;3-month&lt;/font&gt; average daily traded value of
 our common stock on NASDAQ (unless 10% of the lower of the 5-day or
 &lt;font style="WHITE-SPACE: nowrap"&gt;3-month&lt;/font&gt; average daily
 traded value of our common stock on the JASDAQ Market of the Tokyo
 Securities Exchange (&amp;#x201C;TSE&amp;#x201D;) is greater, in which case
 the value from the TSE will be used) as of the date of the
 applicable issuance notice. The price per share is not to be less
 than the greater of $1.29 or the last available closing price of a
 share of common stock on NASDAQ. MCUSA agreed to use its
 commercially reasonable efforts consistent with its customary
 trading and sales practices and applicable laws, rules and
 regulations to sell shares of our common stock and is to sell such
 shares by any method permitted by law deemed to be &amp;#x201C;at the
 market&amp;#x201D;. We agreed to pay MCUSA an aggregate commission rate
 of 7.0% of the gross proceeds of any common stock sold under this
 agreement. MCUSA is under no obligation to purchase shares pursuant
 to this agreement and there are no assurances that MCUSA will be
 successful in selling shares. Our proceeds will depend on the
 number of shares of our common stock sold to MCUSA and the per
 share purchase price of each transaction. The agreement with MCUSA
 provides both MCUSA and us the right to terminate the agreement in
 our sole discretion upon giving five business days written notice.
 Through November&amp;#xA0;5, 2013, we have generated gross and net
 proceeds of $51.0 thousand and $47.4 thousand, respectively, under
 this agreement on sales of 20,000 shares of our common stock at
 prices ranging from $2.52 to $2.58 per share.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Common Stock Purchase
 Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We made no
 sales of our common stock to Aspire subsequent to
 September&amp;#xA0;30, 2013, and we terminated the common stock
 purchase agreement with Aspire on October&amp;#xA0;17, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3_6">P1Y8M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_4">-3257</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_66D3D72B-C351-4CF4-9576-65B727EAD4DA_1_0">&lt;div&gt;
 &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;7. Income
 Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;In accordance
 with the authoritative guidance for income taxes under ASC 740, a
 deferred tax asset or liability is determined based on the
 difference between the financial statements and the tax basis of
 assets and liabilities as measured by the enacted tax rates, which
 will be in effect when these differences reverse. We provide a
 valuation allowance against net deferred assets unless, based upon
 the available evidence, it is more likely than not that the
 deferred tax assets will be realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;We recognize the
 impact of a tax position in the financial statements only if that
 position is more likely than not of being sustained upon
 examination by taxing authorities, based on the technical merits of
 the position. Our practice is to recognize interest and/or
 penalties related to income tax matters in income tax
 expense.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;We are subject
 to income taxation in the U.S., California and foreign
 jurisdictions, of which currently no years are under examination.
 Our tax years for 2000 and forward are subject to examination by
 the U.S. and state tax authorities due to the carry-forward of
 unutilized net operating losses and research and development
 credits. During the three and nine months ended September&amp;#xA0;30,
 2013 and 2012, income tax expense recognized related to
 intercompany service income earned by our Japanese subsidiary,
 MediciNova Japan, Inc.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_60B21184-4286-4291-B0C2-E2B6F363FCE6_1_400004">1212882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_33DFC35B-91AE-4BAD-BFA6-359A1FCD46F9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
 Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
 prepared the accompanying unaudited consolidated financial
 statements in accordance with accounting principles generally
 accepted in the U.S. for interim financial information.
 Accordingly, they do not include all of the information and
 disclosures required by generally accepted accounting principles
 for complete financial statements. In the opinion of management,
 all adjustments of a normal recurring nature necessary for the fair
 presentation of our financial position, results of operations and
 cash flow for the interim periods presented have been included.
 Operating results for the three and nine months ended
 September&amp;#xA0;30, 2013 are not necessarily indicative of the
 results that may be expected for the year ending December&amp;#xA0;31,
 2013 or for any other period. For further information, see the
 financial statements and disclosures thereto for the year ended
 December&amp;#xA0;31, 2012 in our Annual Report on Form 10-K as filed
 with the Securities and Exchange Commission on March&amp;#xA0;28,
 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_57340C41-A1E5-4508-A613-E25F89CEA6CF_2_3">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_38E0CE05-8F17-473A-B81B-9300BBBA1756_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;6. Stock-Based
 Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three
 months ended September&amp;#xA0;30, 2013 and 2012, stock-based
 compensation expense related to stock options and the employee
 stock purchase plan was approximately $198,000 and $179,000,
 respectively, and was recorded as a component of general and
 administrative expense (approximately $128,000 and $111,000,
 respectively) and research and development expense (approximately
 $70,000 and $68,000, respectively). For the nine months ended
 September&amp;#xA0;30, 2013 and 2012, stock-based compensation expense
 related to stock options and the employee stock purchase plan was
 approximately $719,000 and $540,000, respectively, and was recorded
 as a component of general and administrative expense (approximately
 $455,000 and $325,000, respectively) and research and development
 expense (approximately $264,000 and $215,000, respectively). During
 the three months ended September&amp;#xA0;30, 2013 and 2012, there were
 no options exercised. During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, 79,462 and 60,000 stock options,
 respectively, were exercised from which proceeds of approximately
 $194,000 and $138,000, respectively, were received. As of
 September&amp;#xA0;30, 2013, there was $1.3 million of unamortized
 compensation expense related to unvested stock option awards which
 is expected to be recognized over a remaining weighted-average
 vesting period of 1.69&amp;#xA0;years.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the
 three and nine months ended September&amp;#xA0;30, 2013, options to
 purchase 0 and 867,500 shares of common stock were granted,
 respectively. During the three and nine months ended
 September&amp;#xA0;30, 2012, options to purchase 735,000 and 750,000
 shares of common stock were granted, respectively. As stock-based
 compensation expense recognized in the accompanying consolidated
 statements of operations and comprehensive loss includes expense
 related to stock option awards ultimately expected to vest, such
 expense should be reduced for estimated forfeitures. The
 authoritative guidance for compensation expense requires
 forfeitures to be estimated at the time of grant and revised, if
 necessary, in subsequent periods if actual forfeitures differ from
 those estimates. As forfeitures have been immaterial in the past
 and are expected to continue to be immaterial, we did not estimate
 any forfeitures during 2012, or during the nine months ended
 September&amp;#xA0;30, 2013. We adjust our stock-based compensation
 expense when any forfeitures occur.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The MediciNova,
 Inc. 2007 Employee Stock Purchase Plan, or ESPP, provides employees
 the right to purchase our common stock through payroll deductions
 (not to exceed 15% of each employee&amp;#x2019;s compensation) at the
 lower of 85% of fair market value at the beginning of or the end of
 each six-month offering period. For the three and nine months ended
 September&amp;#xA0;30, 2013, the number of shares of common stock
 issued under the ESPP was 14,184 and 30,251, respectively, and for
 the three and nine months ended September&amp;#xA0;30, 2012, the number
 of shares of common stock issued under the ESPP was 19,864 and
 35,414, respectively. Shares of common stock available for future
 ESPP issuances at September&amp;#xA0;30, 2013 and 2012 were 234,327 and
 249,578, respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We use the
 Black-Scholes valuation model for determining the estimated fair
 value and the stock-based compensation for stock-based awards to
 employees. The following table provides the assumptions used in the
 Black-Scholes valuation model for the three and nine months ended
 September&amp;#xA0;30, 2013 and 2012. The ESPP assumptions for the
 three months ended September&amp;#xA0;30, 2013 and 2012 are actual
 amounts, and for the nine months ended September&amp;#xA0;30, 2013 and
 2012 are weighted average amounts.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="40%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Stock Options
 assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.70&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected&amp;#xA0;volatility&amp;#xA0;of&amp;#xA0;common&amp;#xA0;stock&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85.76&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;82.22&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;82.14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
 (in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.3&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.3&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;ESPP
 assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.15&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected&amp;#xA0;volatility&amp;#xA0;of&amp;#xA0;common&amp;#xA0;stock&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.60&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;74.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.55&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;75.52&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
 (in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" id="id_3255982_6E623081-ADFC-46B0-9DEE-5F6D4BA4B5EE_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;9. Commitments and
 Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Legal
 Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;We are not
 involved in any material legal proceedings as of September&amp;#xA0;30,
 2013. We may become involved in various disputes and legal
 proceedings which arise in the ordinary course of business or
 otherwise. Our assessment of the likely impact of any pending
 litigation may change over time. An adverse result in any
 litigation matter may occur which could harm our business and
 result in a material liability.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_21">29314</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-2" id="id_3255982_5AFED1D2-7B43-41EA-8618-BDED39FDCAF9_4_700001">3000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_10">14315</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_43">6354</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_16">-7441793</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_11">-7439443</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_21">-9881</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_0">3257</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_11">30635</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_22">-7451674</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_6">-7447838</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_8">4800</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_13">-7441793</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_8">5920</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_13">211962</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_4">5023445</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_34">13299651</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_3">719084</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_35">6650319</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_5">7451095</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_12">2350</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_3_3">400000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_57340C41-A1E5-4508-A613-E25F89CEA6CF_2_1">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_23">4800</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3_4">194000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_5">90966</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_24">-24514</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_3_3">2427650</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_26">13292954</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_31">6697</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_3_1">121666</mnov:WarrantsExercised>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_1_12">-166345</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <mnov:ProceedsFromIssuanceOfPrivatePlacementNet contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_DB62EBC0-A750-459E-8295-A66184C7A815_1_0">3400000</mnov:ProceedsFromIssuanceOfPrivatePlacementNet>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_1003_6">2.44</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_711502x716112_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_2003_7">4.10</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_734171x806301" unitRef="shares" decimals="0" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3003_5">1936237</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <mnov:ProceedsFromIssuanceOfCommonStockNet contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="-5" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3003_9">5500000</mnov:ProceedsFromIssuanceOfCommonStockNet>
  <mnov:ProceedsFromIssuanceOfCommonStockGross contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="-5" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3003_8">6000000</mnov:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_711502x711169_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_1002_13">1.60</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_711502x716112_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_2002_14">3.82</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3002_12">2504532</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-5" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3002_15">5400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <mnov:AgreementTerminationDate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_734171x796264" id="id_3255982_2B54E040-501C-46C7-8810-C8DA052193D3_1001_0">October 17, 2013</mnov:AgreementTerminationDate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_1003_1">455000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_2003_2">264000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x708980" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_1001_1">2904137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x710593" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_2001_0">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x715581" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_3001_2">3876067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3003_0">719000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1003_1">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1003_2">0.8610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x708980" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1003_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x708980" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1003_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2003_6">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2003_7">0.9155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x715677" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2003_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x715677" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2003_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_5_3">35414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_5_4">249578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_18">16273247</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_16">-9677808</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_4_3">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_2_3">8657667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_17">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_03DAF971-22A3-4F6E-8485-D2ECF7329612_4_0">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_4">-768584</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_21">83176</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_5AFED1D2-7B43-41EA-8618-BDED39FDCAF9_5_800001">800000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_10">22027</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_43">10952</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_16">-8527341</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_22">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_11">-8521523</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_21">-2019</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_0">768584</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_11">-103108</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_22">-8529360</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_6">-8524174</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_13">-8527341</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_8">19376</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_13">-395957</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_4">5057802</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_34">1092383</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_3">540385</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_35">-9348601</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_5">9292758</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_12">5818</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_5_3">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_4_4">138000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_5">35519</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_24">-763176</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_4_3">4234956</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_26">1033764</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_31">58619</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_5_1">0</mnov:WarrantsExercised>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_2_12">-664938</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_1004_1">325000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_2004_2">215000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x708980" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_1002_1">3328981</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x710593" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_2002_0">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x715581" unitRef="shares" decimals="INF" id="id_3255982_84B89AEE-D212-424C-B942-B283116F3B63_3002_2">3128686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3004_0">540000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1004_1">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1004_2">0.8214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x708980" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1004_4">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x708980" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1004_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2004_6">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2004_7">0.7552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x715677" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2004_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x715677" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2004_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_29_20130529_0_709650x713713_797208x760742" unitRef="shares" decimals="0" id="id_3255982_89A371CB-E775-46EE-96EF-17A5BF717506_1001_0">158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <mnov:ValueOfConsiderationReceived contextRef="eol_PE402953--1310-Q0010_STD_29_20130529_0_797208x760742" unitRef="iso4217_USD" decimals="0" id="id_3255982_89A371CB-E775-46EE-96EF-17A5BF717506_2001_2">51389</mnov:ValueOfConsiderationReceived>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_1002_3">1.19</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_734171x806301" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3002_2">10% of the lower of the 5-day or 3-month average daily traded value of our  common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <mnov:SalesCommission contextRef="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_734171x806301" unitRef="pure" decimals="3" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3002_4">0.080</mnov:SalesCommission>
  <mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement contextRef="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="0" id="id_3255982_450065D8-E1A3-4A28-B00A-5A57A9A61A90_3002_1">50000</mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_1001_3">1.29</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_734171x806301" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3001_2">10%  of the lower of the 5-day or 3-month average daily traded value of our common  stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <mnov:SalesCommission contextRef="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_734171x806301" unitRef="pure" decimals="3" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3001_4">0.070</mnov:SalesCommission>
  <mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement contextRef="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_734171x806301" unitRef="iso4217_USD" decimals="0" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3001_1">50000</mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_709650x713713" unitRef="shares" decimals="0" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_1001_2">800000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_709650x713713" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_1001_5">2.50</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_711196x710990" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_2001_4">25.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_711196x710990_734171x796264" unitRef="shares" decimals="0" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_3001_1">220000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_734171x796264" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_4001_8">Each share of the Series B Preferred is  convertible into 10 shares of common stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_31_20111031_0_734171x796264" unitRef="iso4217_USD" decimals="-5" id="id_3255982_0F59283B-4FF7-415F-9C38-F5972B6DE5C5_4001_0">7500000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
  <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="eol_PE402953--1310-Q0010_STD_31_20120331_0" unitRef="pure" decimals="2" id="id_3255982_C32F0946-24F0-49BA-9E9F-61EB676AB49C_1_2">0.70</us-gaap:VariableInterestEntityOwnershipPercentage>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0010_STD_31_20120331_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_C32F0946-24F0-49BA-9E9F-61EB676AB49C_1_0">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <mnov:ClassOfWarrantOrRightsExercisablePeriodFromDateOfIssuance contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0" id="id_3255982_37808D93-6311-494F-951A-72E3886AD020_1_2">P15M</mnov:ClassOfWarrantOrRightsExercisablePeriodFromDateOfIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_3">363636</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-6" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_1">1000000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
  <mnov:StockSubscriptionAgreementMaximumNumberOfShares contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_2">3231096</mnov:StockSubscriptionAgreementMaximumNumberOfShares>
  <mnov:SaleDurationForCommonStockUnderPurchaseAgreement contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_4">P2Y</mnov:SaleDurationForCommonStockUnderPurchaseAgreement>
  <mnov:NumberOfConsecutiveBusinessDay contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_8">P12D</mnov:NumberOfConsecutiveBusinessDay>
  <mnov:NumberOfLowestClosingStockPrices contextRef="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="0" id="id_3255982_9A51AA4F-9DF3-47E7-ACC6-E52BA70845E5_3001_7">3</mnov:NumberOfLowestClosingStockPrices>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_1002_8">2.52</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_711502x716112_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_2002_9">2.58</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_734171x806301" unitRef="shares" decimals="0" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3002_7">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <mnov:ProceedsFromIssuanceOfCommonStockNet contextRef="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_734171x806301" unitRef="iso4217_USD" decimals="-2" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3002_6">47400</mnov:ProceedsFromIssuanceOfCommonStockNet>
  <mnov:ProceedsFromIssuanceOfCommonStockGross contextRef="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_734171x806301" unitRef="iso4217_USD" decimals="-2" id="id_3255982_7995D8FA-35A9-4F67-BEB3-630977889558_3002_5">51000</mnov:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE402953--1310-Q0010_STD_365_20071231_0" unitRef="pure" decimals="2" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_1_1">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <mnov:EmployeeStockPurchasePlanSharePurchaseOfferingPeriod contextRef="eol_PE402953--1310-Q0010_STD_365_20071231_0" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_1_2">P6M</mnov:EmployeeStockPurchasePlanSharePurchaseOfferingPeriod>
  <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_39">2882258</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_16">-216337289</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_4">-805837</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:RepaymentsOfOtherDebt contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_33">17605485</us-gaap:RepaymentsOfOtherDebt>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_21">2390282</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_7">-1735212</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_32">15000000</us-gaap:RepaymentsOfDebt>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_10">19159498</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_43">75956</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_16">-303675590</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_18">2829785</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_22">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_19">377205766</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:InterestPaid contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_44">2487343</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_11">-272234157</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_21">-77838</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_0">2364064</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_11">341299</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_22">-303753428</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_6">-285657475</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseOfRestrictedInvestments contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_14">-5982</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_8">-6660</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_13">-272312468</us-gaap:NetIncomeLoss>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_40">43515677</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_8">395150</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_13">343945</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_4">117280813</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_34">231924086</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_3">51110015</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_35">10660849</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_5">288021539</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromOtherDebt contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_28">17605485</us-gaap:ProceedsFromOtherDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_12">78311</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_15">2500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InterestExpense contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_9">3605818</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_23">261645</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_29">14670000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:CostOfRevenue contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_2">1258421</us-gaap:CostOfRevenue>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_5">2105918</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_20">377918240</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_24">-4925948</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_3">169482305</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_27">85572825</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_26">145958179</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_14">98445</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <mnov:DeemedDividendResultingFromConvertiblePreferredStock contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_5_15">31264677</mnov:DeemedDividendResultingFromConvertiblePreferredStock>
  <mnov:RestrictedAssetsCashUnrestrictedUponConversionOfConvertibleNotes contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_41">1881815</mnov:RestrictedAssetsCashUnrestrictedUponConversionOfConvertibleNotes>
  <mnov:ImpairmentChargeGainNetOnInvestmentSecuritiesAndArsPut contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_7">-1735212</mnov:ImpairmentChargeGainNetOnInvestmentSecuritiesAndArsPut>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_31">-1158171</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:ImpairmentOfSublease contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_9">35259</mnov:ImpairmentOfSublease>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_12">378689</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <mnov:AmortizationOfPremiumDiscountOnInvestmentSecuritiesConvertibleNotesAndDebtDiscountAndIssuanceCosts contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_6">1099365</mnov:AmortizationOfPremiumDiscountOnInvestmentSecuritiesConvertibleNotesAndDebtDiscountAndIssuanceCosts>
  <mnov:ProceedsFromConversionOfConvertibleNotes contextRef="eol_PE402953--1310-Q0010_STD_4748_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_3C35CAFA-B77F-403B-B0E3-9A004D5E1582_3_30">1881253</mnov:ProceedsFromConversionOfConvertibleNotes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_4_3">19864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_18">16585172</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_2_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_17">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_3255982_03DAF971-22A3-4F6E-8485-D2ECF7329612_2_0">735000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_5AFED1D2-7B43-41EA-8618-BDED39FDCAF9_3_600001">100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_10">4090</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_16">-2378768</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_11">-2372950</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_21">2864</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_0">83787</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_22">-2375904</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_6">-2362711</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_13">-2378768</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_8">14329</us-gaap:OtherNonoperatingExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_4">1573943</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_5">2446498</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_12">5818</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_4_3">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_2_3">872555</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_4_1">0</mnov:WarrantsExercised>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_1002_1">111000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_2002_2">68000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3002_0">179000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1002_1">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1002_2">0.8222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x708980" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1002_4">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x708980" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1002_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2002_6">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2002_7">0.7434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x715677" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2002_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x715677" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2002_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_BB06D2BA-0382-433D-8154-D4193BE054CE_2_3">14184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_18">22301773</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_1_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_17">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_3255982_03DAF971-22A3-4F6E-8485-D2ECF7329612_1_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_5AFED1D2-7B43-41EA-8618-BDED39FDCAF9_2_500001">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_10">7798</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_16">-2236750</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_11">-2234944</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_21">756</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_22">-2235994</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_6">-2242347</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_13">-2236750</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_8">395</us-gaap:OtherNonoperatingExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_4">1456774</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_5">2242347</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_12">1806</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_2_3">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_3255982_17A33D58-5830-4F4E-8C7F-5203876483EA_1_3">785573</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_3255982_4BD6E50A-8DA7-4D98-AD13-811FDA8275BD_2_1">0</mnov:WarrantsExercised>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_1001_1">128000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_2001_2">70000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_3255982_7EE684E4-5FD3-48E9-B9F8-1799F0D1DEDE_3001_0">198000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1001_1">0.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x708980" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1001_2">0.8576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x708980" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1001_4">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x708980" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_1001_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2001_6">0.0015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x715677" unitRef="pure" decimals="4" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2001_7">0.9160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x715677" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2001_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x715677" unitRef="pure" decimals="3" id="id_3255982_DD6FDCD5-A958-4C19-BD9B-AF8B5A6AD388_2001_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_4748_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2000-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_365_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-11-05</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_711502x716112_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-11-05</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_36_20131105_0_705999x732135_710720x714667_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-11-05</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20120831_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-03-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20111031_0_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20111031_0_711196x710990_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20111031_0_711196x710990">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_31_20111031_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-17</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_30_20131016_0_705999x732135_710720x714667_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-17</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_30_20130430_0_705999x732135_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_29_20130529_0_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-29</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_29_20130529_0_709650x713713_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-29</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x710593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x710593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_711502x716112_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x827742_709650x713713_711502x711169_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_711502x716112_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0_705999x732135_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_22_20130509_0_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x715581_717061x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x713713_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_22_20130509_0_709650x713713_717061x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20121231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20131016_0_705999x732135_710720x714667_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130930_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_711502x716112_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120831_0_705999x827742_709650x713713_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130529_0_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-29</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130417_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-04-17</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20110323_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-03-23</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20131106_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2013-11-06</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20130509_0_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-09</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20120822_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-08-22</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20111031_0_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0010_STD_0_20111031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_Warrants">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>mnov:Warrants</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>